nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—HTR3A—myenteric nerve plexus—colon cancer	0.124	0.593	CbGeAlD
Metoclopramide—Consciousness abnormal—Vincristine—colon cancer	0.0764	0.0966	CcSEcCtD
Metoclopramide—Altered state of consciousness—Vincristine—colon cancer	0.0287	0.0363	CcSEcCtD
Metoclopramide—Trismus—Capecitabine—colon cancer	0.0259	0.0327	CcSEcCtD
Metoclopramide—CYP11B2—renal system—colon cancer	0.0239	0.114	CbGeAlD
Metoclopramide—Akathisia—Irinotecan—colon cancer	0.0233	0.0295	CcSEcCtD
Metoclopramide—Altered state of consciousness—Capecitabine—colon cancer	0.0187	0.0237	CcSEcCtD
Metoclopramide—CYP17A1—renal system—colon cancer	0.0146	0.0698	CbGeAlD
Metoclopramide—Respiratory failure—Vincristine—colon cancer	0.0135	0.0171	CcSEcCtD
Metoclopramide—Supraventricular tachycardia—Capecitabine—colon cancer	0.0132	0.0167	CcSEcCtD
Metoclopramide—Ventricular fibrillation—Capecitabine—colon cancer	0.0113	0.0143	CcSEcCtD
Metoclopramide—Rash maculo-papular—Fluorouracil—colon cancer	0.0112	0.0142	CcSEcCtD
Metoclopramide—CYP11B2—lymph node—colon cancer	0.0112	0.0535	CbGeAlD
Metoclopramide—Hepatotoxicity—Capecitabine—colon cancer	0.0112	0.0142	CcSEcCtD
Metoclopramide—Visual disturbance—Irinotecan—colon cancer	0.00988	0.0125	CcSEcCtD
Metoclopramide—Renal impairment—Irinotecan—colon cancer	0.00984	0.0125	CcSEcCtD
Metoclopramide—HTR3A—digestive system—colon cancer	0.00941	0.0449	CbGeAlD
Metoclopramide—Cardiac arrest—Vincristine—colon cancer	0.00915	0.0116	CcSEcCtD
Metoclopramide—CYP17A1—liver—colon cancer	0.00894	0.0426	CbGeAlD
Metoclopramide—Cardiac arrest—Irinotecan—colon cancer	0.00891	0.0113	CcSEcCtD
Metoclopramide—Cardiac arrest—Fluorouracil—colon cancer	0.00853	0.0108	CcSEcCtD
Metoclopramide—Urinary incontinence—Capecitabine—colon cancer	0.00834	0.0106	CcSEcCtD
Metoclopramide—Hepatotoxicity—Methotrexate—colon cancer	0.00833	0.0105	CcSEcCtD
Metoclopramide—Fluid retention—Capecitabine—colon cancer	0.0082	0.0104	CcSEcCtD
Metoclopramide—Neutropenia—Vincristine—colon cancer	0.00777	0.00983	CcSEcCtD
Metoclopramide—Erectile dysfunction—Vincristine—colon cancer	0.00766	0.00969	CcSEcCtD
Metoclopramide—Neutropenia—Irinotecan—colon cancer	0.00757	0.00958	CcSEcCtD
Metoclopramide—Depression—Vincristine—colon cancer	0.00739	0.00935	CcSEcCtD
Metoclopramide—Jaundice—Irinotecan—colon cancer	0.00704	0.0089	CcSEcCtD
Metoclopramide—CYP17A1—lymph node—colon cancer	0.00685	0.0327	CbGeAlD
Metoclopramide—Hallucination—Vincristine—colon cancer	0.00662	0.00838	CcSEcCtD
Metoclopramide—Atrial fibrillation—Capecitabine—colon cancer	0.00662	0.00837	CcSEcCtD
Metoclopramide—Bradycardia—Irinotecan—colon cancer	0.0066	0.00835	CcSEcCtD
Metoclopramide—Renal impairment—Capecitabine—colon cancer	0.00659	0.00833	CcSEcCtD
Metoclopramide—Respiratory failure—Methotrexate—colon cancer	0.00655	0.00828	CcSEcCtD
Metoclopramide—Agranulocytosis—Fluorouracil—colon cancer	0.00645	0.00816	CcSEcCtD
Metoclopramide—Visual impairment—Irinotecan—colon cancer	0.00624	0.0079	CcSEcCtD
Metoclopramide—Flushing—Irinotecan—colon cancer	0.00601	0.00761	CcSEcCtD
Metoclopramide—Cardiac arrest—Capecitabine—colon cancer	0.00596	0.00754	CcSEcCtD
Metoclopramide—Gynaecomastia—Methotrexate—colon cancer	0.00575	0.00728	CcSEcCtD
Metoclopramide—Muscle spasms—Irinotecan—colon cancer	0.00542	0.00686	CcSEcCtD
Metoclopramide—Asthma—Capecitabine—colon cancer	0.00542	0.00686	CcSEcCtD
Metoclopramide—Bronchospasm—Capecitabine—colon cancer	0.00533	0.00674	CcSEcCtD
Metoclopramide—Agitation—Vincristine—colon cancer	0.00532	0.00673	CcSEcCtD
Metoclopramide—Leukopenia—Vincristine—colon cancer	0.00518	0.00656	CcSEcCtD
Metoclopramide—Neutropenia—Capecitabine—colon cancer	0.00507	0.00641	CcSEcCtD
Metoclopramide—Leukopenia—Irinotecan—colon cancer	0.00505	0.00639	CcSEcCtD
Metoclopramide—Convulsion—Vincristine—colon cancer	0.00502	0.00635	CcSEcCtD
Metoclopramide—Hypertension—Vincristine—colon cancer	0.005	0.00633	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—colon cancer	0.00492	0.00623	CcSEcCtD
Metoclopramide—Hypertension—Irinotecan—colon cancer	0.00487	0.00616	CcSEcCtD
Metoclopramide—Leukopenia—Fluorouracil—colon cancer	0.00484	0.00612	CcSEcCtD
Metoclopramide—Depression—Capecitabine—colon cancer	0.00482	0.00609	CcSEcCtD
Metoclopramide—Oedema—Vincristine—colon cancer	0.00473	0.00598	CcSEcCtD
Metoclopramide—Jaundice—Capecitabine—colon cancer	0.00471	0.00596	CcSEcCtD
Metoclopramide—Convulsion—Fluorouracil—colon cancer	0.00468	0.00592	CcSEcCtD
Metoclopramide—Confusional state—Irinotecan—colon cancer	0.00464	0.00587	CcSEcCtD
Metoclopramide—Oedema—Irinotecan—colon cancer	0.0046	0.00582	CcSEcCtD
Metoclopramide—Agranulocytosis—Capecitabine—colon cancer	0.00451	0.0057	CcSEcCtD
Metoclopramide—Confusional state—Fluorouracil—colon cancer	0.00445	0.00562	CcSEcCtD
Metoclopramide—Hypotension—Vincristine—colon cancer	0.00442	0.00559	CcSEcCtD
Metoclopramide—Bradycardia—Capecitabine—colon cancer	0.00442	0.00559	CcSEcCtD
Metoclopramide—Oedema—Fluorouracil—colon cancer	0.00441	0.00558	CcSEcCtD
Metoclopramide—Tachycardia—Fluorouracil—colon cancer	0.0043	0.00544	CcSEcCtD
Metoclopramide—Hypotension—Irinotecan—colon cancer	0.0043	0.00544	CcSEcCtD
Metoclopramide—Insomnia—Vincristine—colon cancer	0.00428	0.00541	CcSEcCtD
Metoclopramide—CYP2D6—renal system—colon cancer	0.00422	0.0201	CbGeAlD
Metoclopramide—Visual impairment—Capecitabine—colon cancer	0.00418	0.00529	CcSEcCtD
Metoclopramide—Insomnia—Irinotecan—colon cancer	0.00416	0.00527	CcSEcCtD
Metoclopramide—Hypotension—Fluorouracil—colon cancer	0.00412	0.00521	CcSEcCtD
Metoclopramide—Dyspnoea—Irinotecan—colon cancer	0.0041	0.00519	CcSEcCtD
Metoclopramide—Somnolence—Irinotecan—colon cancer	0.00409	0.00518	CcSEcCtD
Metoclopramide—Fatigue—Vincristine—colon cancer	0.00408	0.00516	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—colon cancer	0.00403	0.0051	CcSEcCtD
Metoclopramide—Flushing—Capecitabine—colon cancer	0.00402	0.00509	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—colon cancer	0.00399	0.00505	CcSEcCtD
Metoclopramide—Fatigue—Irinotecan—colon cancer	0.00397	0.00502	CcSEcCtD
Metoclopramide—Dyspnoea—Fluorouracil—colon cancer	0.00393	0.00497	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—colon cancer	0.00392	0.00496	CcSEcCtD
Metoclopramide—Feeling abnormal—Irinotecan—colon cancer	0.00379	0.0048	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—colon cancer	0.00377	0.00477	CcSEcCtD
Metoclopramide—Body temperature increased—Vincristine—colon cancer	0.00374	0.00473	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—colon cancer	0.00371	0.0047	CcSEcCtD
Metoclopramide—Body temperature increased—Irinotecan—colon cancer	0.00364	0.0046	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—colon cancer	0.00363	0.0046	CcSEcCtD
Metoclopramide—Muscle spasms—Capecitabine—colon cancer	0.00363	0.00459	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—colon cancer	0.0036	0.00455	CcSEcCtD
Metoclopramide—Depression—Methotrexate—colon cancer	0.00359	0.00454	CcSEcCtD
Metoclopramide—Tremor—Capecitabine—colon cancer	0.00354	0.00448	CcSEcCtD
Metoclopramide—Urticaria—Fluorouracil—colon cancer	0.0035	0.00443	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—colon cancer	0.00349	0.00441	CcSEcCtD
Metoclopramide—Hypersensitivity—Vincristine—colon cancer	0.00348	0.00441	CcSEcCtD
Metoclopramide—CYP2D6—digestive system—colon cancer	0.00346	0.0165	CbGeAlD
Metoclopramide—Hypersensitivity—Irinotecan—colon cancer	0.00339	0.00429	CcSEcCtD
Metoclopramide—Asthenia—Vincristine—colon cancer	0.00339	0.00429	CcSEcCtD
Metoclopramide—Leukopenia—Capecitabine—colon cancer	0.00338	0.00428	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—colon cancer	0.00336	0.00425	CcSEcCtD
Metoclopramide—Palpitations—Capecitabine—colon cancer	0.00334	0.00422	CcSEcCtD
Metoclopramide—Asthenia—Irinotecan—colon cancer	0.0033	0.00418	CcSEcCtD
Metoclopramide—Hypertension—Capecitabine—colon cancer	0.00326	0.00412	CcSEcCtD
Metoclopramide—Hypersensitivity—Fluorouracil—colon cancer	0.00325	0.00411	CcSEcCtD
Metoclopramide—Diarrhoea—Vincristine—colon cancer	0.00323	0.00409	CcSEcCtD
Metoclopramide—Anxiety—Capecitabine—colon cancer	0.0032	0.00405	CcSEcCtD
Metoclopramide—Diarrhoea—Irinotecan—colon cancer	0.00315	0.00399	CcSEcCtD
Metoclopramide—Dizziness—Vincristine—colon cancer	0.00313	0.00395	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—colon cancer	0.00311	0.00394	CcSEcCtD
Metoclopramide—Confusional state—Capecitabine—colon cancer	0.00311	0.00393	CcSEcCtD
Metoclopramide—Oedema—Capecitabine—colon cancer	0.00308	0.0039	CcSEcCtD
Metoclopramide—Dizziness—Irinotecan—colon cancer	0.00304	0.00385	CcSEcCtD
Metoclopramide—Diarrhoea—Fluorouracil—colon cancer	0.00302	0.00382	CcSEcCtD
Metoclopramide—Tachycardia—Capecitabine—colon cancer	0.00301	0.0038	CcSEcCtD
Metoclopramide—Rash—Vincristine—colon cancer	0.00298	0.00377	CcSEcCtD
Metoclopramide—Dermatitis—Vincristine—colon cancer	0.00298	0.00377	CcSEcCtD
Metoclopramide—Headache—Vincristine—colon cancer	0.00296	0.00375	CcSEcCtD
Metoclopramide—Dizziness—Fluorouracil—colon cancer	0.00292	0.00369	CcSEcCtD
Metoclopramide—Rash—Irinotecan—colon cancer	0.0029	0.00367	CcSEcCtD
Metoclopramide—Dermatitis—Irinotecan—colon cancer	0.0029	0.00367	CcSEcCtD
Metoclopramide—Headache—Irinotecan—colon cancer	0.00288	0.00365	CcSEcCtD
Metoclopramide—Hypotension—Capecitabine—colon cancer	0.00288	0.00364	CcSEcCtD
Metoclopramide—Nausea—Vincristine—colon cancer	0.00281	0.00355	CcSEcCtD
Metoclopramide—Insomnia—Capecitabine—colon cancer	0.00279	0.00353	CcSEcCtD
Metoclopramide—Rash—Fluorouracil—colon cancer	0.00278	0.00352	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—colon cancer	0.00278	0.00351	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—colon cancer	0.00276	0.00349	CcSEcCtD
Metoclopramide—Dyspnoea—Capecitabine—colon cancer	0.00275	0.00348	CcSEcCtD
Metoclopramide—Nausea—Irinotecan—colon cancer	0.00273	0.00346	CcSEcCtD
Metoclopramide—Fatigue—Capecitabine—colon cancer	0.00266	0.00336	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—colon cancer	0.00262	0.00331	CcSEcCtD
Metoclopramide—CYP2D6—liver—colon cancer	0.00258	0.0123	CbGeAlD
Metoclopramide—Feeling abnormal—Capecitabine—colon cancer	0.00254	0.00321	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—colon cancer	0.00252	0.00318	CcSEcCtD
Metoclopramide—Urticaria—Capecitabine—colon cancer	0.00245	0.0031	CcSEcCtD
Metoclopramide—Body temperature increased—Capecitabine—colon cancer	0.00244	0.00308	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—colon cancer	0.00244	0.00308	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—colon cancer	0.00231	0.00293	CcSEcCtD
Metoclopramide—Hypersensitivity—Capecitabine—colon cancer	0.00227	0.00287	CcSEcCtD
Metoclopramide—Asthenia—Capecitabine—colon cancer	0.00221	0.0028	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—colon cancer	0.00214	0.00271	CcSEcCtD
Metoclopramide—Diarrhoea—Capecitabine—colon cancer	0.00211	0.00267	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—colon cancer	0.00207	0.00262	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—colon cancer	0.00204	0.00259	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—colon cancer	0.00204	0.00258	CcSEcCtD
Metoclopramide—Dizziness—Capecitabine—colon cancer	0.00204	0.00258	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—colon cancer	0.00198	0.0025	CcSEcCtD
Metoclopramide—Rash—Capecitabine—colon cancer	0.00194	0.00246	CcSEcCtD
Metoclopramide—Dermatitis—Capecitabine—colon cancer	0.00194	0.00246	CcSEcCtD
Metoclopramide—Headache—Capecitabine—colon cancer	0.00193	0.00244	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—colon cancer	0.00189	0.00239	CcSEcCtD
Metoclopramide—Nausea—Capecitabine—colon cancer	0.00183	0.00232	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—colon cancer	0.00182	0.00231	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—colon cancer	0.00181	0.00229	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—colon cancer	0.00169	0.00214	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—colon cancer	0.00165	0.00208	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—colon cancer	0.00157	0.00199	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—colon cancer	0.00152	0.00192	CcSEcCtD
Metoclopramide—Rash—Methotrexate—colon cancer	0.00145	0.00183	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—colon cancer	0.00144	0.00183	CcSEcCtD
Metoclopramide—Headache—Methotrexate—colon cancer	0.00144	0.00182	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—colon cancer	0.00136	0.00172	CcSEcCtD
